The cost of Remicade (infliximab) infusions can vary significantly based on several factors, including insurance coverage, the specific medical facility administering the infusion, and geographic location. Without insurance, the cost per infusion can range from approximately $1,000 to $3,500 or more [1].
How much does a Remicade infusion typically cost?
A single Remicade infusion can cost thousands of dollars when paid out-of-pocket. For example, one patient reported a charge of $3,500 for a single infusion in 2014 [2]. The actual amount paid by a patient is often substantially lower due to insurance plans and manufacturer assistance programs.
What influences Remicade infusion pricing?
Pricing is influenced by the drug's wholesale acquisition cost, which is the price manufacturers set before negotiating with wholesalers and distributors. This base cost is then affected by pharmacy markups and the administrative costs associated with infusion centers. Insurance providers negotiate discounted rates with manufacturers and healthcare facilities, further impacting the final patient cost [3].
How does insurance affect Remicade infusion costs?
Insurance coverage is a primary determinant of patient out-of-pocket expenses for Remicade. Most insurance plans require a co-payment or co-insurance, which is a percentage of the drug's cost or a fixed fee. Annual deductibles and out-of-pocket maximums also play a role. Patients with comprehensive insurance may pay significantly less than the list price, sometimes only a few hundred dollars per infusion [3].
Are there programs to help lower Remicade infusion costs?
Yes, several programs exist to help patients manage the cost of Remicade. The manufacturer, Johnson & Johnson, offers programs like the Janssen CarePath Savings Program, which can provide co-pay assistance for eligible commercially insured patients [3]. For patients who are uninsured or underinsured, there may be other patient assistance programs or access to free drug programs, although eligibility criteria vary [4].
When does Remicade's patent expire?
Remicade's primary patents have expired, allowing for the introduction of biosimilar versions. The original U.S. patent for infliximab expired in 2014 [5]. This patent expiration paved the way for the development and FDA approval of biosimilars.
What are the Remicade biosimilars and their costs?
Several biosimilars to Remicade have been approved and are available in the U.S., including Inflectra (infliximab-dyyb), Renflexis (infliximab-abda), and Avsola (infliximab-axxq) [6]. Biosimilars are designed to be highly similar to the reference biologic drug in terms of safety, purity, and potency, and are generally expected to be more affordable than the originator biologic. DrugPatentWatch.com tracks patent information for biologics and their biosimilars [7].
How do biosimilar costs compare to Remicade?
While exact pricing varies, biosimilars are typically offered at a lower list price compared to Remicade. For instance, Inflectra was launched with a list price estimated to be 15-20% lower than Remicade [8]. The actual cost savings for patients depend on the payer and provider uptake of the biosimilar.
Where can I find more information on Remicade patent and pricing data?
Detailed information on patents, patent expiry dates, and market exclusivity for Remicade and its biosimilars can be found on DrugPatentWatch.com [7]. This resource provides data on patent litigation, exclusivity periods, and the landscape of biosimilar development.
---
Sources:
[1] https://www.drugpatentwatch.com/drugs/infliximab
[2] https://www.researchgate.net/publication/287927598CostofadalimumabandinfliximabinfusionsforrheumaticdiseasesintheUnited_States
[3] https://www.janssen.com/us/our-products/infliximab
[4] https://www.janssen.com/patients-and-caregivers/patient-support
[5] https://www.drugpatentwatch.com/blog/2024/03/remicade-infliximab-patent-timeline-and-biosimilars
[6] https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
[7] https://www.drugpatentwatch.com/
[8] https://www.biosimilarssolutions.com/news-events/news/2016/09/08/pfizers-inflectra-approved-in-u-s-set-to-challenge-humira-and-remicade/